These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20501635)

  • 21. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.
    Piron M; Loo M; Gothot A; Tassin F; Fillet G; Beguin Y
    Blood; 2001 Jan; 97(2):442-8. PubMed ID: 11154221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.
    Veng-Pedersen P; Freise KJ; Schmidt RL; Widness JA
    J Pharm Pharmacol; 2008 Oct; 60(10):1321-34. PubMed ID: 18812025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells.
    Wickrema A; Krantz SB; Winkelmann JC; Bondurant MC
    Blood; 1992 Oct; 80(8):1940-9. PubMed ID: 1391953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects.
    Pérez-Ruixo JJ; Krzyzanski W; Hing J
    Clin Pharmacokinet; 2008; 47(6):399-415. PubMed ID: 18479174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control.
    Souillard A; Audran M; Bressolle F; Gareau R; Duvallet A; Chanal JL
    Br J Clin Pharmacol; 1996 Sep; 42(3):355-64. PubMed ID: 8877027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of recombinant human erythropoietin on the immune function of premature rats].
    Tu HL; Ye HM; Wang J; Huang DM
    Zhonghua Er Ke Za Zhi; 2003 Feb; 41(2):99-103. PubMed ID: 14759308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.
    Saleh MI; Nalbant D; Widness JA; Veng-Pedersen P
    Am J Physiol Regul Integr Comp Physiol; 2013 May; 304(9):R772-81. PubMed ID: 23485870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythropoietin response and route of administration.
    Taylor JE; Belch JJ; Fleming LW; Mactier RA; Henderson IS; Stewart WK
    Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.
    Chapel SH; Veng-Pedersen P; Schmidt RL; Widness JA
    Exp Hematol; 2001 Apr; 29(4):425-31. PubMed ID: 11301182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats.
    Yoon WH; Park SJ; Kim IC; Lee MG
    Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):227-40. PubMed ID: 9226757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship of erythropoietin and iron metabolism to red blood cell production in humans.
    Adamson JW
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):9-15. PubMed ID: 8202725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat.
    Berridge MV; Fraser JK; Carter JM; Lin FK
    Blood; 1988 Sep; 72(3):970-7. PubMed ID: 3416080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematological indices of erythropoietin administration in athletes.
    Casoni I; Ricci G; Ballarin E; Borsetto C; Grazzi G; Guglielmini C; Manfredini F; Mazzoni G; Patracchini M; De Paoli Vitali E
    Int J Sports Med; 1993 Aug; 14(6):307-11. PubMed ID: 7691771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control.
    Varlet-Marie E; Gaudard A; Audran M; Bressolle F
    Sports Med; 2003; 33(4):301-15. PubMed ID: 12688828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation on the feasibility of large-volume autologous red blood cells donation: A pilot trial in a small cohort of Chinese.
    Wu J; Chen G; Wang L; Wang P; Han Y; Yang L; Ouyang X
    J Clin Apher; 2023 Aug; 38(4):447-456. PubMed ID: 36950971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.
    Brockmöller J; Köchling J; Weber W; Looby M; Roots I; Neumayer HH
    Br J Clin Pharmacol; 1992 Dec; 34(6):499-508. PubMed ID: 1493082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens.
    D'Cunha R; Schmidt R; Widness JA; Mock DM; Yan X; Cress GA; Kuruvilla D; Veng-Pedersen P; An G
    Eur J Pharm Sci; 2019 Oct; 138():105013. PubMed ID: 31340188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.
    Yan X; Lowe PJ; Fink M; Berghout A; Balser S; Krzyzanski W
    J Clin Pharmacol; 2012 Nov; 52(11):1624-44. PubMed ID: 22162538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic model for chemotherapy-induced anemia in rats.
    Woo S; Krzyzanski W; Jusko WJ
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):123-33. PubMed ID: 17891399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply.
    Loo M; Beguin Y
    Blood; 1999 May; 93(10):3286-93. PubMed ID: 10233880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.